Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-080450
Filing Date
2025-06-02
Accepted
2025-06-02 18:32:13
Documents
1
Period of Report
2025-05-29

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 5757
  Complete submission text file 0000950170-25-080450.txt   7223
Mailing Address SOLAZYME, INC. 225 GATEWAY BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address
CLARK IAN T (Reporting) CIK: 0001336504 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-41947 | Film No.: 251016533

Mailing Address 5980 HORTON STREET SUITE 550 EMERYVILLE CA 94608
Business Address 5980 HORTON STREET SUITE 550 EMERYVILLE CA 94608 5106268331
Kyverna Therapeutics, Inc. (Issuer) CIK: 0001994702 (see all company filings)

EIN.: 831365441 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)